82_FR_12267 82 FR 12228 - Patient Safety Organizations: Expired Listing From the Surgical Momentum PSO

82 FR 12228 - Patient Safety Organizations: Expired Listing From the Surgical Momentum PSO

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality

Federal Register Volume 82, Issue 39 (March 1, 2017)

Page Range12228-12229
FR Document2017-03999

The Patient Safety and Quality Improvement Act of 2005, 42 U.S.C. 299b-21 to b-26, (Patient Safety Act) and the related Patient Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient Safety Rule), published in the Federal Register on November 21, 2008, 73 FR 70732-70814, establish a framework by which hospitals, doctors, and other health care providers may voluntarily report information to Patient Safety Organizations (PSOs), on a privileged and confidential basis, for the aggregation and analysis of patient safety events. The Patient Safety Rule authorizes AHRQ, on behalf of the Secretary of HHS, to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be ``delisted'' by the Secretary if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule, when a PSO chooses to voluntarily relinquish its status as a PSO for any reason, or when a PSO's listing expires. The listing from the Surgical Momentum PSO has expired and AHRQ has delisted the PSO accordingly.

Federal Register, Volume 82 Issue 39 (Wednesday, March 1, 2017) 
[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Pages 12228-12229]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03999]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Patient Safety Organizations: Expired Listing From the Surgical 
Momentum PSO

AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department 
of Health and Human Services (HHS).

ACTION: Notice of delisting.

-----------------------------------------------------------------------

SUMMARY: The Patient Safety and Quality Improvement Act of 2005, 42 
U.S.C. 299b-21 to b-26, (Patient Safety Act) and the related Patient 
Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient 
Safety Rule), published in the Federal Register on November 21, 2008, 
73 FR 70732-70814, establish a framework by which hospitals, doctors, 
and other health care providers may voluntarily report information to 
Patient Safety Organizations (PSOs), on a privileged and confidential 
basis, for the aggregation and analysis of patient safety events. The 
Patient Safety Rule authorizes AHRQ, on behalf of the Secretary of HHS, 
to list as a PSO an entity that attests that it meets the statutory and 
regulatory requirements for listing. A PSO can be ``delisted'' by the 
Secretary if it is found to no longer meet the requirements of the 
Patient Safety Act and Patient Safety Rule, when a PSO chooses to 
voluntarily relinquish its status as a PSO for any reason, or when a 
PSO's listing expires. The listing from the Surgical Momentum PSO has 
expired and AHRQ has delisted the PSO accordingly.

DATES: The directories for both listed and delisted PSOs are ongoing 
and reviewed weekly by AHRQ. The delisting was effective at 12:00 
Midnight ET (2400) on January 21, 2017.

ADDRESSES: Both directories can be accessed electronically at the 
following HHS Web site: http://www.pso.ahrq.gov/listed.

FOR FURTHER INFORMATION CONTACT: Eileen Hogan, Center for Quality 
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Room 06N94B, 
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone 
(local):

[[Page 12229]]

(301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local): (301) 
427-1130; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Background

    The Patient Safety Act authorizes the listing of PSOs, which are 
entities or component organizations whose mission and primary activity 
are to conduct activities to improve patient safety and the quality of 
health care delivery.
    HHS issued the Patient Safety Rule to implement the Patient Safety 
Act. AHRQ administers the provisions of the Patient Safety Act and 
Patient Safety Rule relating to the listing and operation of PSOs. The 
Patient Safety Rule authorizes AHRQ to list as a PSO an entity that 
attests that it meets the statutory and regulatory requirements for 
listing. A PSO can be ``delisted'' if it is found to no longer meet the 
requirements of the Patient Safety Act and Patient Safety Rule, when a 
PSO chooses to voluntarily relinquish its status as a PSO for any 
reason, or when a PSO's listing expires. Section 3.108(d) of the 
Patient Safety Rule requires AHRQ to provide public notice when it 
removes an organization from the list of federally approved PSOs.
    The Surgical Momentum PSO, PSO number P0154, a component entity of 
the Surgical Momentum, LLC, chose to let its listing expire by not 
seeking continued listing. Accordingly, the Surgical Momentum PSO was 
delisted effective at 12:00 Midnight ET (2400) on January 21, 2017.
    More information on PSOs can be obtained through AHRQ's PSO Web 
site at http://www.pso.ahrq.gov.

Sharon B. Arnold,
Acting Director.
[FR Doc. 2017-03999 Filed 2-28-17; 8:45 am]
BILLING CODE 4160-90-P

12228 Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices indicated. The applications will also be Healthcare Research and Quality, 5600 www.AHRQ.gov no later than Friday, available for inspection at the offices of Fishers Lane, Mail Stop 06E37A, March 17, 2017. the Board of Governors. Interested Rockville, Maryland, 20857, (301) 427– Sharon B. Arnold, persons may express their views in 1456. For press-related information, writing on the standards enumerated in Acting Director. please contact Alison Hunt at (301) 427– the BHC Act (12 U.S.C. 1842(c)). If the [FR Doc. 2017–03998 Filed 2–28–17; 8:45 am] 1244 or Alison.Hunt@ahrq.hhs.gov. proposal also involves the acquisition of BILLING CODE 4160–90–P If sign language interpretation or other a nonbanking company, the review also includes whether the acquisition of the reasonable accommodation for a nonbanking company complies with the disability is needed, please contact the DEPARTMENT OF HEALTH AND standards in section 4 of the BHC Act Food and Drug Administration (FDA) HUMAN SERVICES (12 U.S.C. 1843). Unless otherwise Office of Equal Employment Opportunity and Diversity Management Agency for Healthcare Research and noted, nonbanking activities will be Quality conducted throughout the United States. on (301) 827–4840, no later than Friday, Unless otherwise noted, comments March 17, 2017. The agenda, roster, and Patient Safety Organizations: Expired regarding each of these applications minutes will be available from Ms. Listing From the Surgical Momentum must be received at the Reserve Bank Bonnie Campbell, Committee PSO indicated or the offices of the Board of Management Officer, Agency for Governors not later than March 22, Healthcare Research and Quality, 5600 AGENCY: Agency for Healthcare Research 2017. Fishers Lane, Rockville, Maryland, and Quality (AHRQ), Department of A. Federal Reserve Bank of St. Louis 20857. Ms. Campbell’s phone number is Health and Human Services (HHS). (David L. Hubbard, Senior Manager) (301) 427–1554. ACTION: Notice of delisting. P.O. Box 442, St. Louis, Missouri 63166–2034. Comments can also be sent SUPPLEMENTARY INFORMATION: SUMMARY: The Patient Safety and electronically to Quality Improvement Act of 2005, 42 I. Purpose Comments.applications@stls.frb.org: U.S.C. 299b–21 to b–26, (Patient Safety 1. Cross County Bancshares, Inc., The National Advisory Council for Act) and the related Patient Safety and Wynne, Arkansas; to acquire additional Healthcare Research and Quality is Quality Improvement Final Rule, 42 shares, for a total of 24.9 percent of authorized by Section 941 of the Public CFR part 3 (Patient Safety Rule), Central Bank, Little Rock, Arkansas. Health Service Act, 42 U.S.C. 299c. In published in the Federal Register on accordance with its statutory mandate, November 21, 2008, 73 FR 70732– Board of Governors of the Federal Reserve System, February 24, 2017. the Council is to advise the Secretary of 70814, establish a framework by which hospitals, doctors, and other health care Yao-Chin Chao, the Department of Health and Human providers may voluntarily report Assistant Secretary of the Board. Services and the Director of AHRQ on information to Patient Safety [FR Doc. 2017–03938 Filed 2–28–17; 8:45 am] matters related to AHRQ’s conduct of its Organizations (PSOs), on a privileged BILLING CODE 6210–01–P mission including providing guidance and confidential basis, for the on (A) priorities for health care research, aggregation and analysis of patient (B) the field of health care research safety events. The Patient Safety Rule DEPARTMENT OF HEALTH AND including training needs and authorizes AHRQ, on behalf of the HUMAN SERVICES information dissemination on health Secretary of HHS, to list as a PSO an care quality and (C) the role of the entity that attests that it meets the Agency for Healthcare Research and Agency in light of private sector activity statutory and regulatory requirements Quality and opportunities for public private for listing. A PSO can be ‘‘delisted’’ by partnerships. The Council is composed the Secretary if it is found to no longer Meeting of the National Advisory of members of the public, appointed by meet the requirements of the Patient Council for Healthcare Research and the Secretary, and Federal ex-officio Safety Act and Patient Safety Rule, Quality members specified in the authorizing when a PSO chooses to voluntarily AGENCY: Agency for Healthcare Research legislation. relinquish its status as a PSO for any and Quality (AHRQ), HHS. reason, or when a PSO’s listing expires. II. Agenda The listing from the Surgical ACTION: Notice of public meeting. The Council meeting will convene at Momentum PSO has expired and AHRQ SUMMARY: In accordance with section 8:30 a.m., with the call to order by the has delisted the PSO accordingly. 10(a) of the Federal Advisory Committee DATES: The directories for both listed Council Chair and approval of previous Act, 5 U.S.C. App. 2, this notice and delisted PSOs are ongoing and Council summary notes. The meeting is announces a meeting of the National reviewed weekly by AHRQ. The Advisory Council for Healthcare open to the public and will be available via webcast at delisting was effective at 12:00 Midnight Research and Quality. ET (2400) on January 21, 2017. www.webconferences.com/ahrq. The DATES: The meeting will be held on ADDRESSES: Both directories can be meeting will begin with an update on Friday, March 24, 2017, from 8:30 a.m. accessed electronically at the following asabaliauskas on DSK3SPTVN1PROD with NOTICES AHRQ’s current research, programs, and to 2:45 p.m. HHS Web site: http:// initiatives. The agenda will feature ADDRESSES: The meeting will be held at www.pso.ahrq.gov/listed. discussions on the learning health care the Hubert H. Humphrey Building, FOR FURTHER INFORMATION CONTACT: system, Medical Expenditure Panel Room 800, 200 Independence Avenue Eileen Hogan, Center for Quality Survey (MEPS), and AHRQ’s work in SW., Washington, DC 20201. Improvement and Patient Safety, AHRQ, rural areas. The final agenda will be FOR FURTHER INFORMATION CONTACT: available on the AHRQ Web site at 5600 Fishers Lane, Room 06N94B, Jaime Zimmerman, Designated Rockville, MD 20857; Telephone (toll Management Official, at the Agency for free): (866) 403–3697; Telephone (local): VerDate Sep<11>2014 18:09 Feb 28, 2017 Jkt 241001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\01MRN1.SGM 01MRN1

Federal Register / Vol. 82, No. 39 / Wednesday, March 1, 2017 / Notices 12229 (301) 427–1111; TTY (toll free): (866) committee is to provide advice and Reducing the Risk of Human 438–7231; TTY (local): (301) 427–1130; recommendations to the Agency on Immunodeficiency Virus Transmission Email: pso@ahrq.hhs.gov. FDA’s regulatory issues. At least one by Blood and Blood Products. SUPPLEMENTARY INFORMATION: portion of the meeting will be closed to On April 5, 2017, in open session, the the public. committee will hear overview Background DATES: The meeting will be held on presentations on the research programs The Patient Safety Act authorizes the April 4, 2017, from 8:30 a.m. to 3:45 in the Laboratory of Emerging Pathogens listing of PSOs, which are entities or p.m. and on April 5, 2017, from 8:30 in the Division of Emerging component organizations whose a.m. to 12 p.m. Transfusion-Transmitted Diseases, mission and primary activity are to ADDRESSES: The meeting will be held at Office of Blood Research and Review, conduct activities to improve patient Tommy Douglas Conference Center, Center for Biologics Evaluation and safety and the quality of health care 10000 New Hampshire Ave., Silver Research, FDA. At the conclusion of the delivery. Spring, MD 20903. The conference open session, the meeting will be closed HHS issued the Patient Safety Rule to center’s telephone number is 240–645– to permit discussion where disclosure implement the Patient Safety Act. 4000. Answers to commonly asked would constitute an unwarranted AHRQ administers the provisions of the questions including information invasion of personal privacy in Patient Safety Act and Patient Safety regarding special accommodations due accordance with 5 U.S.C 552b(c)(6). Rule relating to the listing and operation to a disability, visitor parking, and During the closed session, the of PSOs. The Patient Safety Rule transportation may be accessed at: Committee will discuss the research authorizes AHRQ to list as a PSO an http://www.tommydouglascenter.com. progress made by staff involved in the entity that attests that it meets the intramural research programs and make FOR FURTHER INFORMATION CONTACT: statutory and regulatory requirements recommendations regarding their Bryan Emery or Joanne Lipkind, Center for listing. A PSO can be ‘‘delisted’’ if personnel actions and staffing decisions. for Biologics Evaluation and Research, it is found to no longer meet the FDA intends to make background Food and Drug Administration, 10903 requirements of the Patient Safety Act material available to the public no later New Hampshire Ave., Bldg. 71, Rm. and Patient Safety Rule, when a PSO than 2 business days before the meeting. 6132, Silver Spring, MD 20993–0002, chooses to voluntarily relinquish its If FDA is unable to post the background 240–402–8054, 240–402–8106, material on its Web site prior to the status as a PSO for any reason, or when bryan.emery@fda.hhs.gov, meeting, the background material will a PSO’s listing expires. Section 3.108(d) joanne.lipkind@fda.hhs.gov; or FDA be made publicly available at the of the Patient Safety Rule requires Advisory Committee Information Line, location of the advisory committee AHRQ to provide public notice when it 1–800–741–8138 (301–443–0572 in the meeting, and the background material removes an organization from the list of Washington, DC area). A notice in the will be posted on FDA’s Web site after federally approved PSOs. Federal Register about last minute the meeting. Background material is The Surgical Momentum PSO, PSO modifications that impact a previously available at: http://www.fda.gov/ number P0154, a component entity of announced advisory committee meeting AdvisoryCommittees/Calendar/ the Surgical Momentum, LLC, chose to cannot always be published quickly default.htm. Scroll down to the let its listing expire by not seeking enough to provide timely notice. appropriate advisory committee meeting continued listing. Accordingly, the Therefore, you should always check the link. Surgical Momentum PSO was delisted Agency’s Web site at http:// Procedure: Interested persons may effective at 12:00 Midnight ET (2400) on www.fda.gov/AdvisoryCommittees/ present data, information, or views, January 21, 2017. default.htm and scroll down to the orally or in writing, on issues pending More information on PSOs can be appropriate advisory committee meeting before the committee. Written obtained through AHRQ’s PSO Web site link, or call the advisory committee submissions may be made to the contact at http://www.pso.ahrq.gov. information line to learn about possible person on or before March 28, 2017. modifications before coming to the Oral presentations from the public will Sharon B. Arnold, meeting. For those unable to attend in be scheduled between approximately Acting Director. person, the meeting will also be [FR Doc. 2017–03999 Filed 2–28–17; 8:45 am] 10:50 a.m. to 11:20 a.m. and will be available via Webcast. The Webcast will scheduled between approximately 3:15 BILLING CODE 4160–90–P be available at the following link for p.m. to 3:45 p.m. on April 4, 2017. Oral both days: April 4, 2017, 115th Meeting presentations from the public will be of the Blood Products Advisory scheduled between approximately 10:15 DEPARTMENT OF HEALTH AND Committee—Day 1 at: http:// HUMAN SERVICES a.m. and 11:15 a.m. on April 5, 2017. fda.yorkcast.com/webcast/Play/ Those individuals interested in making bb044b891a7b48ff82cc30b18ece526e1d; formal oral presentations should notify Food and Drug Administration April 5, 2017, 115th Meeting of the the contact person and submit a brief [Docket No. FDA–2017–N–0001] Blood Products Advisory Committee— statement of the general nature of the Day 2 at: http://fda.yorkcast.com/ evidence or arguments they wish to Blood Products Advisory Committee; webcast/Play/b4068ead1c874966860584 present, the names and addresses of Notice of Meeting b421dcfd231d. proposed participants, and an indication of the approximate time asabaliauskas on DSK3SPTVN1PROD with NOTICES AGENCY: Food and Drug Administration, SUPPLEMENTARY INFORMATION: HHS. Agenda: On April 4, 2017, in open requested to make their presentation on ACTION: Notice. session, the Committee will discuss or before March 20, 2017. Time allotted Recombinant Human Coagulation Factor for each presentation may be limited. If SUMMARY: The Food and Drug IX, GlycoPEGylated. In the afternoon, in the number of registrants requesting to Administration (FDA) announces a open session, the Committee will hear speak is greater than can be reasonably forthcoming public advisory committee an update presentation on a summary of accommodated during the scheduled meeting of the Blood Products Advisory responses to Docket FDA–2016–N–1502: open public hearing session, FDA may Committee. The general function of the Blood Donor Deferral Policy for conduct a lottery to determine the VerDate Sep<11>2014 18:09 Feb 28, 2017 Jkt 241001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\01MRN1.SGM 01MRN1


Document Created: 2017-03-01 03:39:13
Document Modified: 2017-03-01 03:39:13
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of delisting.
DatesThe directories for both listed and delisted PSOs are ongoing and reviewed weekly by AHRQ. The delisting was effective at 12:00 Midnight ET (2400) on January 21, 2017.
ContactEileen Hogan, Center for Quality Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Room 06N94B, Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone (local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local): (301) 427-1130; Email: [email protected]
FR Citation82 FR 12228 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR